Assessing care models implemented in primary health care for persons with Alzheimer’s disease and related disorders
The Canadian Consortium on Neurodegeneration in Aging (CCNA) is the largest initiative in dementia research ever undertaken in Canada. In its second phase of funding, CCNA will bring together over 310 researchers from 39 universities in eight provinces across Canada, and these researchers will continue to foster collaborations with other international studies on dementia. The CCNA was established in 2014—based on a partnership between the CIHR 13 other public and private funding bodies. From 2019 to 2024, CCNA will receive $46 million from the Canadian Institutes of Health Research (CIHR) and 11 other partner organizations, including the Alzheimer Society of Canada (ASC) and NBHRF. CCNA’s mission is to foster research collaborations across disciplines and universities on cognitive decline and dementia which impact over 400,000 Canadians today, and will impact as many as 1.5 million Canadians by 2031.
To accelerate and synergize research nationwide, CCNA researchers work under three research themes (Prevention, Treatment, and Quality of Life) within nineteen research teams, exploring a range of topics. In Phase II, the researchers will also benefit from programs that will build their capacity in engaging people living with dementia in research; exploring Indigenous research topics and healthcare issues; and conducting research on special topics related to women, gender, sex, and dementia.
Our research team, ROSA (Research on Organization of Healthcare Services for Alzheimers), is led by Drs. Howard Bergman and Isabelle Vedel and investigates how to provide innovative care for persons living with dementia. In Phase II, our team secured $1,520,000 from CIHR and matching partners to conduct this project.